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Tetrahydro-imidazo[4,5,l-jk][1,4]-benzodiazepin-2 (1 H)one (TIBO) is a noncompetitive non nucleotide 
antiretroviral drug with a specific allosteric binding site of HIV-1 RT. The conformational analysis shows 
that the effect of the drug depends on the potential energy which varied due to the beta rotatable 
dihedral angles (N6 - C15 - C16 = C17) of the TIBO side chain. The change of binding energy between 
TIBO and HIV-RT due to the variation in beta rotatable dihedral angles was determined. The theoretical 
simulation for a step size of 30 degrees variation from 0 to 90 degree changes was performed. The 
derived binding energies range from 0 to 8 kcal/mol. Changes in the beta dihedral angle conformation 
critically affects the binding energy. TIBO derivatives that affect the beta angle can change the binding 
energy between drug and HIV-RT and this can affect drug activity. 
 





Human immunodeficiency virus (HIV) inhibitors targeted 
at the virus-associated reverse transcriptase (RT) can be 
divided into two groups, depending on whether they are 
targeted at the substrate or nonsubstrate binding site. To 
the first group belong the dideoxynucleosides, dioxolane 
derivatives, oxetanocin analogues and carbocyclic der-
ivatives which need to be phosphorylated intra-cellularly 
to their triphosphate forms before they act as competitive 
inhibitors or alternate substrates (chain terminators) of 
HIV RT (De Clercq, 1992). The second group consists of 
drugs that interact noncompetitively with a specific 
allosteric binding site of HIV-1 RT (De Clercq, 1992). The 
tetrahydro-imidazo[4,5,l-jk][1,4]-benz-odiazepin-2 (1 
H)one (TIBO) is an important member of this group (De 
Clercq, 1992; White et al., 1991; Pauwels et al., 1992). 
TIBO blocks the chemical reaction, but does not 
interfere with nucleotide binding or the nucleotide-
induced conformational change (Spence et al., 1995). 
Rather, in the presence of saturating concentrations of 
the inhibitors, it is bound tightly (Kd, 100 nM), but non-
productively (Spence et al., 1995). According to the study 
of Gupta and Garg (1996), the anti-HIV activity of the 
derivatives of TIBO that have been found to elicit their 
action through the allosteric inhibition of the enzyme viral 
RT is analysed in relation to the physicochemical 
properties of the molecules and significant correlations 
are obtained between the activity and the hydrophobic 
constant and some dummy parameters of substituents 
Gupta and Garg (1996). The main action of TIBO occurs 
after the complex formation between TIBO and HIV-RT. 
The intermolecular binding energy between the active 
side chain of TIBO and binding pocket of HIV-RT is about 
8 kCal/mol (Saen-oon et al., 2005). However, the conf-
ormational analysis shows that the effect of the drug dep-
ends on the potential energy which varied due to the beta 
rotatable dihedral angles (N6 - C15 - C16 = C17) of the 
TIBO side chain. In this work, the change of binding en-
ergy between TIBO and HIV-RT due to the variation in 
beta rotatable dihedral angles was determined. 
 
 
MATERIALS AND METHODS 
 
Basic concepts in binding between TIBO and HIV-RT  
   
As previously mentioned, binding between the active side chains of 
TIBO and binding pocket of HIV-RT is the main reaction. The active 
side chain of TIBO posed two important parts for the reaction, alpha 
(C5 - N6 - C15 - C16) and beta (N6 - C15 - C16 = C17) dihedral 





Quantum chemical analysis for binding energy  
 
This is a calculation-based study. Basically, each chemical reaction 
poses it specific required reaction energy. The primary assumption 
in this study is the required reaction energy for the pharmacological 
reaction between TIBO and HIV-RT is equal to 8 kCal/mol when 
occurred within a planar angle (interphase angle = 90 degree) 
(Saen-oon et al., 2005). In this work, the theoretical simulation for a 
step size of 30 degrees variation from 0 to 90 degree changes was 
performed. Calculation for the energy in each binding scenario was 




Table 1. Changing in binding energy due to the variation of 
beta dihedral angle. 
 








RESULTS AND DISCUSSION 
 
The stepwise changing in binding energy corresponding 
to the variation of beta dihedral angle is presented in 
Table 1. The derived binding energies range from 0 
kcal/mol to 8 kcal/mol  
Inhibitors of HIV-RT are important drugs for the trea-
tment of acquired immuno-deficiency syndrome (AIDS) 
(Arnold et al., 1996). Numerous potent inhibitors of RT 
have been described including all of the drugs that have 
been currently licensed for the treatment of AIDS. Failure 
of antiretroviral drug therapy can be resulted from both of 
the viral mutants and the conformation of antiretroviral 
drug. TIBO derivatives exert their effects by binding to a 
hydrophobic pocket in the RT heterodimer and that muta-
tions which give rise to drug resistance directly interfere 
with the interactions between the TIBO and HIV-1 RT 
(Boyer et al., 1994). There are some researches to clarify 
the structure of TIBO-HIV-RT complex (Ren et al., 1995, 
1999). In this theoretical research, the energy change 
corresponding to the conformational change within TIBO 
was investigated. 
It was observed that change in the beta dihedral angle 
conformation critically affects the binding energy. 
Decreased biding energy can be observed.   This  implies  




the difficulties for occurrence of reaction and further 
implies the drug resistance. Based on the results in this 
study, it seems that any TIBO derivatives that affect the 
beta angle can change the binding energy between drug 
and HIV-RT and this can affect drug activity. Proper mod-
ifications to the TIBO group of inhibitors might enhance 
their binding and hence, potentially, their therapeutic effi-
cacy (Ren et al., 1995). This explains some derivatives 
are highly active while the others are not. Also, it can rev-
eal the fact that the same drug is effective for sometimes 
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